Monogram Biosciences, Inc., a California based leader in molecular diagnostics for improving drug treatment of serious diseases, today announced presentations made by its scientists related to the company’s VeraTag™ assays. The presentations were made at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Geneva, Switzerland.
The presentations dealt with what are called EGFR/HER receptors, known to be significant to the proliferation of many different cancers, such as breast cancer. The presentations were about Monogram’s developments in the field of assays used for detecting these receptors in cancerous tissues, information that is critical for associated drug development and treatment regimens. The first presentation outlined the development of sensitive and specific assays in fixed tumor cell lines. The second presentation described the validation of these assays as providing quantitative and accurate measurements in human tumor tissue.
William Young, Monogram CEO, said “HERmark™, our recently launched breast cancer assay, is bringing new options to breast cancer patients with quantitative measurements of HER2 total protein and HER2:HER2 homodimer. This week’s presentations in Geneva evidence Monogram’s expanding portfolio of assays and the growing reach of the VeraTag technology.”
Gordon Parry, Ph.D., Monogram’s VP of Oncology R&D, added, “With our VeraTag platform, we can make precise and quantitative measurements of protein complexes that have not previously been possible. The data presented this week, on the HER1 and HER3 total protein assays, the HER1:HER1 homodimer assay and the activated HER1:HER2 heterodimer assay, provide support for the use of these assays in drug development programs not only in breast cancer, our current focus, but also in other cancer types.”
Monogram Biosciences focuses on the development of innovative diagnostic products. The goal is to help healthcare providers better match underlying molecular elements of an individual patient’s disease to specific drug treatments, and to help pharmaceutical companies develop more effective therapeutics and vaccines. The company is best known for its HIV and cancer related assay products.
About QualityStocks:
QualityStocks’ Small Cap Stock Newsletter is a free service that collects data from hundreds of Small-Cap online Investment Newsletters into one free Daily Newsletter Report.
Sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net
The Quality Stocks Daily Stock Report http://video.qualitystocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment